A Clinical Pharmacokinetic Study of Tacrolimus and Sirolimus Combination Immunosuppression Comparing Simultaneous to Separated Administration

@article{McAlister2002ACP,
  title={A Clinical Pharmacokinetic Study of Tacrolimus and Sirolimus Combination Immunosuppression Comparing Simultaneous to Separated Administration},
  author={Vivian Charles McAlister and Kamran Mahalati and Kevork M. Peltekian and Albert D. Fraser and Allan S. Macdonald},
  journal={Therapeutic Drug Monitoring},
  year={2002},
  volume={24},
  pages={346-350}
}
The pharmacokinetic (PK) interaction between tacrolimus (TAC) and sirolimus (SRL), similarly structured immunosuppressive compounds that share binding proteins, is unknown. The combination of SRL with cyclosporin (CsA) has been studied, and a 4-hour interval between dosing of the two drugs is recommended even though it is inconvenient for patients and may affect compliance. Twenty-five liver and kidney–pancreas transplant recipients treated with a combination of SRL and low-dose TAC completed… 

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

TLDR
It is suggested that sirolimus and tacrolimus concentration monitoring be performed when changes in dosing are made for either drug regimen, due to the complexity of anti-rejection immunosuppressive therapy dosing.

Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients

  • M. SchubertR. Venkataramanan R. Sindhi
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
The short half‐life of SRL in children may support twice‐daily administration early after liver and small intestinal transplantation and aggressive therapeutic drug monitoring must be used to individualize therapy and avoid serous adverse events.

Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial

TLDR
It is concluded that in adult renal transplant recipients, EVL significantly decreases TAC oral bioavailability in a dose-dependent manner and this regimen of low EVL exposure plus standard TAC exposure avoids wound healing problems with good efficacy.

Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing

  • D. CattaneoS. Merlini N. Perico
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
It is found that dose‐normalized SRL trough levels were significantly higher in patients treated with cyclosporine and SRL, and different immunosuppressants significantly interfere with SRL bioavailability.

Sirolimus pharmacokinetic differences between children and adults

TLDR
The pharmacokinetics of sirolimus are reported in a group of pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy, with a higher apparent clearance in children aged zero to five yr and a substantial interpatient variability in the apparent clearance.

Long‐Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients

TLDR
Dose reductions of tacrolimus in both study groups were reflected by concordant decreasing pharmacokinetic exposure parameters, which illustrates the common clinical practice of reducing the dose of calcineurin inhibitor as time elapses after transplantation.

Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients

TLDR
The results show an inverse correlation between age and required tacrolimus dose, wide interindividual variation, and greater exposure with steroid‐free regimen despite no change in trough level.
...

References

SHOWING 1-10 OF 21 REFERENCES

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration

TLDR
Preliminary analysis suggested that values for the pharmacokinetic parameters of sirolimus vary among races (black versus nonblack) but not among genders, and linear dose proportionality was suggested.

Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

TLDR
Tacrolimus provides the clinician with an effective option for patients requiring immunosuppression and, with a different tolerability and efficacy profile to cyclosporin, it will better allow the tailoring of therapy to meet the needs of individual patients.

Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation

TLDR
Therapeutic drug monitoring is important to avoid unnecessary toxicity, but the lower limit has not been fully defined, clearly, many patients with <5 ng/ml have excellent hepatic function, although careful monitoring continues.

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

TLDR
Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.

An immunoassay for the measurement of sirolimus.

A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

TLDR
The addition of either 2 mg/ day sirolimus or 5 mg/day siro Limus to CsA/corticosteroid therapy significantly reduces the incidence of acute rejection episodes in primary mismatched renal allograft recipients, without an increase in immunosuppressant-related side effects, at 6 months and at 1 year after transplantation.

Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action

  • S. Sehgal
  • Biology, Medicine
    Therapeutic drug monitoring
  • 1995
Summary Rapamycin (Sirolimus, Rapamune), a potent immunosuppressive agent, has been demonstrated to have remarkable activity in inhibiting allograft rejection in animal models of transplantation. It